Results 1 to 10 of about 23,209 (275)

The Cholinergic Drug Galantamine Alleviates Oxidative Stress Alongside Anti-inflammatory and Cardio-Metabolic Effects in Subjects With the Metabolic Syndrome in a Randomized Trial [PDF]

Frontiers in Immunology, 2021
Background: The metabolic syndrome (MetS) is an obesity-associated disorder of pandemic proportions and limited treatment options. Oxidative stress, low-grade inflammation and altered neural autonomic regulation, are important components and drivers of ...
Carine Teles Sangaleti, Carine Teles Sangaleti, Keyla Yukari Katayama, Kátia De Angelis, Kátia De Angelis, Tércio Lemos de Moraes, Amanda Aparecida Araújo, Heno F. Lopes, Heno F. Lopes, Cleber Camacho, Luiz Aparecido Bortolotto, Lisete Compagno Michelini, Maria Cláudia Irigoyen, Peder S. Olofsson, Peder S. Olofsson, Douglas P. Barnaby, Kevin J. Tracey, Valentin A. Pavlov, Fernanda Marciano Consolim Colombo, Fernanda Marciano Consolim Colombo   +19 more
doaj   +3 more sources

Galantamine ameliorates experimental pancreatitis

Molecular Medicine, 2023
Background Acute pancreatitis is a common and serious inflammatory condition currently lacking disease modifying therapy. The cholinergic anti-inflammatory pathway (CAP) is a potent protective anti-inflammatory response activated by vagus nerve-dependent
Dane A. Thompson, Tea Tsaava, Arvind Rishi, Sam J. George, Tyler D. Hepler, Daniel Hide, Valentin A. Pavlov, Michael Brines, Sangeeta S. Chavan, Kevin J. Tracey   +9 more
doaj   +4 more sources

Galantamine attenuates autoinflammation in a mouse model of familial mediterranean fever

Molecular Medicine, 2022
Background Autoinflammatory diseases, a diverse group of inherited conditions characterized by excessive innate immune activation, have limited therapeutic options.
Ibrahim T. Mughrabi, Mahendar Ochani, Mirza Tanovic, Ping Wang, Betty Diamond, Barbara Sherry, Valentin A. Pavlov, Seza Ozen, Daniel L. Kastner, Jae Jin Chae, Yousef Al-Abed   +10 more
doaj   +2 more sources

Galantamine-loaded PLGA nanoparticles reduce oxidative stress and inflammation in a rat model of spinal cord injury [PDF]

Scientific Reports
Spinal cord injury (SCI) represents a debilitating condition with no effective treatments currently available. Previous research demonstrated that galantamine improves functional outcomes in SCI models. However, systemic administration results in limited
Fernanda Stapenhorst Franca, Laura Elena Sperling, Marcelo Garrido dos Santos, Cristian Euzebio Teixeira, Tiago Franco de Oliveira, Patrick Turck, Adriane Bello Klein, Patricia Pranke   +7 more
doaj   +2 more sources

Pharmacological Aspects of the Acetylcholinesterase Inhibitor Galantamine

Journal of Pharmacological Sciences, 2011
.: Several lines of evidence suggest that cholinergic deficits may contribute to the pathophysiology of psychiatric disorders as well as Alzheimer’s disease.
Yukio Ago, Ken Koda, Kazuhiro Takuma, Toshio Matsuda   +3 more
doaj   +3 more sources

The cholinergic drug galantamine ameliorates acute and subacute peripheral and brain manifestations of acute respiratory distress syndrome in mice [PDF]

Scientific Reports
Acute respiratory distress syndrome (ARDS) is a life-threatening form of acute lung injury (ALI), which is a common cause of respiratory failure and high mortality in critically ill patients.
Aidan Falvey, Santhoshi P. Palandira, Saher Chaudhry, Aisling Tynan, Fernanda Marciano Consolim-Colombo, Christine N. Metz, Michael Brines, Eric H. Chang, Sangeeta S. Chavan, Kevin J. Tracey, Valentin A. Pavlov   +10 more
doaj   +2 more sources

Galantamine [PDF]

Reactions Weekly, 2017
In 1906, Alois Alzheimer, a psychiatrist from Munich, Germany, described a new mental illness, which is a progressively damaging brain disorder, leading to neurodegeneration, erosion of basic intellectual functions along with histological changes, and ultimately the patient’s death.
John C. Courtney, Efrain Antonio Gonzalez   +1 more
  +4 more sources

Long-term effect of galantamine on cognitive function in patients with Alzheimer’s disease versus a simulated disease trajectory: an observational study in the clinical setting

Neuropsychiatric Disease and Treatment, 2017
Ryoko Nakagawa,1 Takashi Ohnishi,1 Hisanori Kobayashi,1 Toshio Yamaoka,2 Tsutomu Yajima,3 Ai Tanimura,4 Toshiya Kato,4 Kazutake Yoshizawa1 1Evidence Generation Department, Medical Affairs Division, 2Clinical Data Management Department, R&D Division,
Nakagawa R, Ohnishi T, Kobayashi H, Yamaoka T, Yajima T, Tanimura A, Kato T, Yoshizawa K   +7 more
doaj   +1 more source

Design and Physicochemical Characterization of Hybrid PLGA-Curcumin/Carbon Dot Nanoparticles for Sustained Galantamine Release: A Proof-of-Concept Study. [PDF]

Biomolecules
Samiotaki C, Nanaki S, Bikiaris RE, Christodoulou E, Kyzas GZ, Barmpalexis P, Bikiaris DN.   +6 more
europepmc   +3 more sources

Galantamine plasma concentration and cognitive response in Alzheimer’s disease [PDF]

PeerJ, 2019
Background Galantamine has been approved for the treatment of Alzheimer’s disease (AD). However, there are few studies which have reported the association between cognitive responses and galantamine plasma concentration.
Yi-Ting Lin, Mei-Chuan Chou, Shyh-Jong Wu, Yuan-Han Yang   +3 more
doaj   +2 more sources